Navigation Links
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Date:4/20/2012

SEATTLE, April 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the first quarter of 2012.

First Quarter Financial ResultsFor the quarter ended March 31, 2012, total operating expenses were $18.1 million compared to $20.1 million for the same period in 2011. Net loss attributable to common shareholders decreased 66% to $17.4 million ($0.09 per share) for the quarter ended March 31, 2012 compared to a net loss attributable to common shareholders of $51.0 million ($0.35 per share) for the same period in 2011. The decrease in net loss attributable to CTI's common shareholders is primarily due to a decrease in deemed dividends and total operating expenses. CTI had approximately $27.4 million in cash and cash equivalents as of March 31, 2012.

Recent Highlights

  • In February 2012, the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") granted a positive opinion for conditional approval of CTI's MAA for Pixuvri as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma ("NHL").
  • In April 2012, CTI entered into an agreement to acquire a highly selective JAK2 inhibitor, pacritinib, which is a phase 3 candidate for treating patients with myelofibrosis ("MF").
  • "With potential approval of our MAA for Pixuvri in the E.U. to treat adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma and tosedostat gearing up to initiate a pivotal phase 3 trial in relapsed or refractory acute myeloid leukemia/myelodysplastic syndromes ("MDS") later this year, the agreement to acquire pacritinib, a highly selective JAK2 inhibitor, rounds out our novel late stage oncology drug portfolio placing us in a select group of biotech companies.  Our oncology drug portfolio now spans across
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
    (Date:7/28/2014)... DC (PRWEB) July 28, 2014 It’s a ... GI Bill benefits to further their post-secondary education are failing ... a study released this year. And according to an analysis ... this shortfall is veteran students’ uninformed choice of college majors, ... The details of the study: Some 51.7 percent of post-9/11 ...
    (Date:7/28/2014)... STATION, Texas , July 28, 2014   The ... a 177-key, 4-star boutique hotel in the heart of The Atlas ... Photo - http://photos.prnewswire.com/prnh/20140725/130455 Photo ... within ATLAS , The Atlas ... rooms and suites, a sleek restaurant and bar, a wellness spa, ...
    (Date:7/26/2014)... NY (PRWEB) July 26, 2014 ... provides key market data on the Canada Endoscopy ... millions of US dollars, volume (in units) and ... - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization ... Full Report at http://www.marketresearchreports.biz/analysis/213254 . , The ...
    Breaking Biology Technology:String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5
    ... Calif., Oct. 27 Beckman,Coulter, Inc. (NYSE: ... and marketer,of products that simplify, automate, and ... Garrett, Beckman Coulter,s chairman,president and chief executive ... Conference on Tuesday, November 4, 2008 at ...
    ... 27 Dr. Annie De Groot, CEO of,EpiVax, is ... about,the activation of natural regulatory T cells by IgG ... were published in the,October 8 issue of the prestigious ... Hematology., In an accompanying editorial, Rachel Caspi of ...
    ... Facility, NEW YORK, Oct. 27 NeoStem, Inc. ... pre-disease collection,processing and long-term storage of adult stem cells ... on a private placement financing,in the amount of $250,000. ... stem cell collection network in the New York City ...
    Cached Biology Technology:Publication on 'Tregitopes' in Blood Journal of October 2008 2NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc. 2NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc. 3
    (Date:7/27/2014)... prevalence studies to date, researchers from the U.K. provide ... hepatitis C virus (HCV). Findings published in Hepatology, a ... Liver Diseases, indicate that genotype 1 is the most ... which one-third reside in East Asia. Genotype 3, at ... prevalent, followed by genotypes 2, 4, 6, and 5. ...
    (Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
    (Date:7/25/2014)... people lived on the land now called California, and ... availability of plants they used for food, fuel, tools, ... maintain desired habitat and natural resources. , Frank Lake, ... Station, will lead a field trip to ... Society of America,s 99th Annual Meeting, in Sacramento, Cal. ...
    Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
    ... Health have discovered specific molecular and signaling events by ... showed that low levels of Vitamin D, comparable to ... the inflammatory cascade, while levels considered adequate did inhibit ... 1, 2011, issue of The Journal of Immunology ...
    ... an outbreak of airborne H5N1 influenza in humans needs to ... can safely continue H5N1 research and share the results among ... mBio , the online open-access journal of the American Society ... been at the center of heated discussions in science and ...
    ... are frequently reminded of the complex challenges Africa faces ... the sub-Saharan region. Dealing with hunger and famine ... and needs a global effort. Overcoming these challenges in ... and requires increased efforts in research and development. ...
    Cached Biology News:Researchers discover how vitamin D inhibits inflammation 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3Cutting-edge science creating solutions for African agriculture 2